CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Inclusion Criteria: * Has a diagnosis of PKAN confirmed by: a) genetic testing confirming 2 pathogenic or likely pathogenic mutations, or (b) typical findings on exam and brain MR imaging with only one pathogenic mutation +/- a second likely pathogenic or VOUS in PANK2, or (c) typical findings on exam and brain MR imaging with a single likely pathogenic or VOUS in PANK2, or (d) be a symptomatic sibling of a proband subject meeting a, b or c. * Be between 3 months old and 89 years old. * Be able to take study product by mouth or feeding tube. * Be willing and able to complete study procedures / telephone visits / blood draws independently, OR have a caregiver / parent willing and able to assist with these tasks. * Be enrolled or willing to enroll in the PKANready natural history study (eIRB 10832). * Be resident in North America (US or Canada) for the duration of the trial. Exclusion Criteria: * Have had exposure to a putative PANK2 bypass therapeutic agent in the 30 days prior to screening. * Be concurrently enrolled in another interventional clinical trial. * Have concurrent medical or other condition expected to preclude completion of study procedures of confound the assessment of clinical and laboratory measures of safety.